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  ABSTRACT 
  Objectives      To conﬁ  rm the effectiveness and safety 
of the interleukin 6-receptor antagonist tocilizumab in 
patients with rheumatoid arthritis (RA) in a setting close 
to real-life medical care in Germany.   
  Methods      A multicentre open-label phase IIIb study 
was undertaken. Patients with active RA with a 28-joint 
Disease Activity Score (DAS28) >3.2 despite previous 
disease-modifying antirheumatic drugs (DMARDs) 
were treated with tocilizumab 8 mg/kg every 4 weeks. 
The primary end point was the proportion of patients 
achieving LDAS ≤3.2   at week 24; secondary end points 
included American College of Rheumatology (ACR), 
European League Against Rheumatism (EULAR) or Clinical 
Disease Activity Index (CDAI) responses and decrease in 
acute phase. Analyses in subgroups such as rheumatoid 
factor (RF)-positive versus RF-negative patients and 
patients with an inadequate response to treatment with 
DMARDs (DMARD-IR) versus those with an inadequate 
response to tumour necrosis factor (TNF) antagonists 
(TNF antagonist-IR) were performed. Safety was 
assessed by adverse event documentation.   
  Results      286 patients were treated and 83.6% 
completed the study. 41.6% had previously been treated 
with TNF antagonists. 57% of the intention-to-treat 
patients achieved the primary end point of LDAS, 47.6% 
achieved DAS remission <2.6 and a EULAR ‘good 
response’ was achieved by 54.9%; ACR50/70 response 
rates at week 24 were 50.7% and 33.9%, respectively. 
The mean±SD decrease in CDAI from baseline to week 
24 was 71±29%. C reactive protein levels normalised 
rapidly within 1 week. Major improvements in fatigue, 
pain and morning stiffness were observed in the ﬁ  rst 
4 weeks and further improved until week 24. DAS28, 
EULAR and ACR responses at week 24 did not differ 
between RF-positive and RF-negative patients. TNF 
antagonist-naive patients responded better than patients 
who had previously failed on TNF antagonists. The safety 
proﬁ  le of tocilizumab was comparable to that previously 
observed in the phase III trial programme. Serious 
infections were observed in 3.1% of patients.   
  Conclusions      Tocilizumab is highly effective in a 
setting close to real-life medical care with a rapid and 
sustained improvement in signs and symptoms of RA. A 
manageable safety proﬁ  le was seen over the 24-week 
study  period.      
  INTRODUCTION 
  During the past years the treatment of rheuma-
toid arthritis (RA) has changed considerably.    1        2    In 
addition to treatment with conventional disease-
modifying antirheumatic drugs (DMARDs), bio-
logical agents have emerged with the capability of 
speciﬁ  cally targeting single components within the 
inﬂ  ammatory cascade    3    such as inhibiting tumour 
necrosis factor (TNF) α    4    or interleukin (IL)-1,    5    tar-
geting CD20 B cells    6    or interfering with T cell 
activation by blocking CD80/86:CD28 signalling.    7    
However, approximately 70% of patients still fail 
to achieve remission and approximately 29–54% 
do not show signiﬁ  cant improvement with TNFα 
antagonists.    8     –      10    The development of other innova-
tive targeted therapies with alternative modes of 
action is therefore needed. 
  Tocilizumab, a recombinant humanised mono-
clonal IgG  1   antihuman interleukin 6-receptor anti-
body represents such a new treatment option in 
patients with moderate to severe active RA who 
have either responded inadequately or were intol-
erant to previous treatment with one or more 
DMARDs or TNF antagonists. 
  In clinical studies it was shown that tocilizumab 
is well tolerated and efﬁ  cacious in alleviating the 
signs and symptoms of RA,    11     –      15    as well as inhibit-
ing radiological progression.    16        17    The results of these 
studies led to its approval by the European Medicines 
Agency (EMA) in January 2009 and by the FDA in 
January 2010. The clinical phase II and III studies, 
however, required strict eligibility criteria and rigid 
adherence to a comprehensive schedule of study-
related events. In the phase IIIb study (TAMARA), 
the efﬁ  cacy and safety of tocilizumab in a setting 
closer to daily practice was investigated.   
  METHODS 
    Study design and patients 
  TAMARA (  T  ocilizumab   A  nd D  M  ARDs: 
  A  chievements in   R  heumatoid   A  rthritis), a multi-
centre open-label non-controlled single-arm study, 
was performed at 70 centres in Germany from 
September 2008 to July 2009. Men and women 
aged >18 years with moderate to severe active RA 
of ≥6 months’ duration who had an inadequate 
clinical response (28-joint Disease Activity Score 
(DAS28) >3.2) to a stable dose of conventional 
or biological DMARDs were included. Patients 
were treated with tocilizumab 8 mg/kg every 4 
weeks at day 1 and weeks 4, 8, 12, 16 and 20 in 
addition to their stable background DMARD. The 
primary outcome was the proportion of patients 
reaching a DAS ≤3.2 after 24 weeks. Secondary 
outcomes were improvements in the European 
▶  Additional data are published 
online only. To view these ﬁ  les 
please visit the journal online at 
(http://ard.bmj.com).
  1 Charité-Universitätsmedizin 
Berlin, Department of 
Rheumatology and Clinical 
Immunology, Free University and 
Humboldt University of Berlin, 
Berlin, Germany 
  2 Rheumatologische  Praxis, 
München, Germany 
  3 Rheumazentrum  Ruhrgebiet 
Herne, Herne, Germany 
  4  Department III, Nephrology 
and Rheumatology, University 
Clinic Hamburg UKE, Hamburg, 
Germany 
  5  Department I, Internal 
Medicine, University of Cologne, 
Cologne, Germany 
      Correspondence  to   
Gerd-R Burmester, Charité-
Universitätsmedizin Berlin, 
Department of Rheumatology 
and Clinical Immunology, 
Free University and Humboldt 
University of Berlin, Charitéplatz 
1, 10117 Berlin;  
gerd.burmester@charite.de                                  
        Effectiveness  and  safety  of  the  interleukin  6-receptor 
antagonist tocilizumab after 4 and 24 weeks in 
patients with active rheumatoid arthritis: the ﬁ  rst 
phase IIIb real-life study (TAMARA)   
    Gerd  R    Burmester,   1       E    Feist,   1       H    Kellner,   2       J    Braun,   3       C    Iking-Konert,   4       A    Rubbert-Roth   5    
08_annrheumdis139725.indd   755 08_annrheumdis139725.indd   755 3/22/2011   5:38:54 PM 3/22/2011   5:38:54 PMExtended report
Ann Rheum Dis 2011;70:755–759. doi:10.1136/ard.2010.139725 756
consisting of 24.5% men and 75.5% women aged 18–84 years. 
All but one patient was pretreated with DMARDs, mostly with 
methotrexate (95.1%) or leﬂ   unomide (60.1%), and 41.6% of 
patients were pretreated with TNFα antagonists. During the 
study, concomitant methotrexate was used by 72.0%, leﬂ  unomide 
by 19.6%, glucocorticoids by 70.6% and nine patients received 
tocilizumab monotherapy (see ﬁ  gure 3 in the online supplement). 
Deviations from the protocol leading to exclusion from the per 
protocol population (PP) occurred in 153 patients (deviations with 
a frequency of >5% are listed in ﬁ  gure in the online supplement), 
but only 11 patients (3.3%) had to be withdrawn because of pro-
tocol violations. Thus, 133 patients were valid for inclusion in 
the strict PP population. Overall, the protocol deviations had no 
League Against Rheumatism (EULAR) response, DAS remis-
sion, American College of Rheumatology (ACR) responses and 
the safety of tocilizumab with regard to adverse events (AEs), 
laboratory assessments and physical examination. In addition, 
effects on health-related quality of life outcomes in the study 
population were assessed. Details of the study population, sta-
tistics and methods are shown in the online supplement.     
  RESULTS 
  Patients 
  After screening of 334 patients, 286 patients were enrolled in 
the study and 85.6% completed the 24-week period and were 
included in the primary analysis intention-to-treat (ITT) population 
 Figure  1        (A) Response categories of DAS28 (DAS remission, LDAS, clinically signiﬁ  cant reduction in DAS delta >1.2) in TNF antagonist-IR and 
DMARD-IR patients. ‘Data as observed’, missing data were evaluated as non-response. (B) Change in DAS28 from baseline to week 4 and week 24 
(percentage of patients in LDAS and DAS remission after 24 weeks depending on their DAS at baseline). (C) Percentage of patients with no swollen 
joints and/or no tender joints at weeks 4 and 24 (LOCF). DAS28, 28-joint Disease Activity Score; DMARD-IR, inadequate response to disease-
modifying antirheumatic drugs; LDAS, Low Disease Activity Score; LCOF, last observation carried forward; SJC, swollen joint count; TJC, tender joint 
count; TNF antagonist-IR, inadequate response to tumour necrosis factor antagonists.       
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response, DAS remission in 48.2%, LDAS in 57.1%) which was 
comparable to the results observed in the entire cohort.   
  The signiﬁ  cant results obtained with the DAS28 assessments 
were conﬁ  rmed by improvements in all other secondary efﬁ  cacy 
parameters. As shown in   ﬁ  gure 2A,   the self-reported ‘patient take 
home form’ indicated that the strongest effects had already appeared 
within the ﬁ  rst 4 weeks of treatment (ie, following the very ﬁ  rst infu-
sion) in pain, morning stiffness and fatigue. Also, in other patient-
reported outcomes, improvement in health-related quality of life 
measured by the Health Assessment Questionnaire-Disease Index 
(HAQ-DI) was reported (  ﬁ  gure 2B  ), and also in the Short Form-36 
(SF-36) which showed an improvement in physical functioning and 
vitality as well as in social functioning and mental health.   
  The mean global satisfaction of patients with the treatment 
according to the Treatment Satisfaction Questionnaire for 
Medication was 74.7±25.9%. At week 24, 72.8% of patients 
in the DMARD-IR subgroup and 65.5% of patients in the TNF 
antagonist-IR subgroup were satisﬁ   ed with the effectiveness 
of the treatment and 89.7% in the DMARD-IR subgroup and 
88.5% in the TNF antagonist-IR subgroup were satisﬁ  ed with 
the tolerability. Global satisfaction with the medication was 
reported by 77.8% of patients in the DMARD-IR subgroup and 
71.6% of patients in the TNF antagonist-IR subgroup.   
  Safety 
  The safety proﬁ  le of tocilizumab was comparable to that previ-
ously observed. A total of 242 patients (84.6%) experienced at 
least one AE during the study. Most of the AEs were mild or 
moderate and resolved by the end of the study. No deaths were 
reported. Sixteen patients (5.6%) were withdrawn from treat-
ment due to AEs and 10 (3.5%) due to study drug-related AEs. 
Table 3 in the online supplement shows the most common study 
drug-related AEs and differences in the incidence of AEs between 
patients pretreated with DMARDs or TNF antagonists. 
  Fifteen patients (5.2%) had serious AEs related to the study 
drug, which were mostly infections. In nine patients with infec-
tions (3.1%) at least one infection was serious (see table 3 in 
online supplement for details). Three patients prematurely dis-
continued the study due to serious infections. No serious AEs 
related to the study drug occurred at frequencies ≥1%. 
  AEs of special interest occurred in 156 patients (54.5%) and 
in 120 (42.0%) at least one was rated as drug-related. The high-
est incidence rates were seen in lipid elevations (29.7% in total; 
23.4% drug-related) and infections (28.7% in total; 17.8% drug-
related). The mean changes in the lipid panel (total cholesterol, 
triglycerides, high-density lipoprotein and low-density lipopro-
tein) indicated mild increases and only in a few patients (n=15) 
detectable inﬂ  uence on the study outcomes; the results of the ITT 
and PP populations were nearly identical.   
  Efﬁ  cacy 
  Analysis of the primary efﬁ  cacy variable showed that 163 of 
the 286 patients (57.0%) in the ITT population achieved a Low 
Disease Activity Score (LDAS) at week 24 (63.2% with DMARD 
pretreatment and 50.4% with TNF antagonist pretreatment). 
More DMARD-IR patients (53.4%) than TNF antagonist-IR 
patients (41.2%) reached DAS remission (  ﬁ  gure 1A  ).   
  Tocilizumab showed a very early onset of action. The mean 
DAS28 at baseline was 6.0±1.0 points. After the ﬁ  rst infusion 
the mean DAS28 decreased by 21.5±18.0% within 1 week and 
by 40.1±19.9% within 4 weeks. 75.2% of patients experienced 
a clinically signiﬁ  cant reduction by ≥1.2 DAS28 points, 40.9% 
achieved an LDAS and 23.1% were in DAS28 remission after 
only one infusion. Thereafter, mean disease activity continuously 
decreased: by week 24 mean DAS28 decreased from 6.0±1.0 
points at baseline to 2.6±1.5 points (reduction of 56.8±22.5%). 
  Most of the patients had a high disease activity at baseline; 
79.2% had a DAS28 >5.1 which decreased by 16.1% at week 
4, and only 6.6% persistently had a DAS >5.1 at week 24 while 
most (53.0%) of the patients achieved LDAS and 44% were 
in DAS28 remission. Of the patients with a baseline DAS28 
between >3.2 and ≤5.1 (n=54), 74% achieved LDAS and 61% 
achieved DAS28 remission at week 24 (  ﬁ  gure 1B  ). 
  ACR response rates at week 24 showed that 65.0% of the 
patients met the criteria for an ACR20 response, 50.7% for an 
ACR50 response and 33.9% for an ACR70 response. These 
improvements were seen in all components of the ACR core 
set, notably in the number of swollen and tender joints which 
signiﬁ  cantly decreased in both DMARD-IR and TNF antago-
nist-IR patients (  table 1  ). After 24 weeks, 33% of patients had 
a tender joint count (TJC) of 0 and 42% had a swollen joint 
count (SJC) of 0; 26% of patients had both TJC and SJC of 
0 (  ﬁ  gure 1C  ). Accordingly, the Clinical Disease Activity Index 
decreased by 70.9±29.3% from 34.7±12.5 to 11.3±11.5 within 
24 weeks.   
  A subgroup analysis of RF-positive versus RF-negative 
patients did not show a statistically signiﬁ  cant difference in 
DAS28, EULAR or ACR responses at week 24 ( table 2 ), although 
RF-positive patients had a higher DAS28 than RF-negative 
patients at baseline (6.1 vs 5.7). Moreover, age, sex, body mass 
index, concomitant diseases and pretreatment did not differ 
between the two groups (data not shown). In addition, the 
subgroup of patients with concomitant leﬂ  unomide  therapy 
achieved a signiﬁ  cant clinical improvement (55.4% EULAR good 
  Table  1         American College of Rheumatology core set components at baseline, week 4 and week 24 (last observation carried forward) in TNF 
antagonist-IR and DMARD-IR subgroups of patients   
 Component 
 Baseline   Week  4   Week  24 
 TNF  antagonist-IR   DMARD-IR   TNF  antagonist-IR   DMARD-IR   TNF  antagonist-IR   DMARD-IR 
SJC/28 (n) 12.3±8.4 13.3±7.3 6.6±5.9 6.2±7.1 3.8±4.9 3.0±4.9
TJC/28 (n) 20.7±14.2 20.0±11.2 13.1±13.1 10.3±11.4 8.7±11.7 5.3±8.4
CRP (mg/l) 26.7±28.6 20.7±32.2 7.1±17.2 4.5±12.8 2.7±4.3 3.3±9.5
ESR (mm/h) 40.5±24.4 35.6±20.3 11.7±14.8 9.3±12.5 7.2±10.1 6.9±9.1
VAS physician disease activity (mm) 64.6±16.6 61.2±19.4 38.1±23.8 27.9±20.2 23.9±23.2 13.2±14.9
VAS patient pain (mm) 67.0±18.0 60.4±21.5 44.6±27.1 36.0±26.7 30.6±24.8 23.6±26.3
HAQ-DI 1.67±0.62 1.33±0.65 1.33±0.64 1.01±0.69 1.20±0.72 0.84±0.74
   Data  shown  as  mean±SD. 
  While there was no difference between patients pretreated with one or two TNF antagonists, patients with three TNF antagonists in the history showed a lesser response which, due 
to low numbers, was not statistically signiﬁ  cant (data not shown) 
  CRP, C reactive protein; DMARD-IR, inadequate response to disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-
Disease Index; SJC, swollen joint count; TJC, tender joint count; TNF, tumour necrosis factor; TNF antagonist-IR, inadequate response to TNF antagonists; VAS, visual analogue scale.     
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had failed with a TNF antagonist. Concomitant DMARD therapy 
was continued, which was most often   methotrexate (72.0%) but 
19.6% of the patients were treated with leﬂ  unomide, reﬂ  ecting 
the ‘real-life’ scenario. The high number of protocol deviations 
also reﬂ  ects a ‘real-life’ scenario, but only a few patients had to 
be withdrawn from the study. Protocol violations did not inﬂ  u-
ence study outcome parameters as the results of the ITT and PP 
populations were virtually identical. 
  The TAMARA study conﬁ  rmed the good efﬁ  cacy observed in 
different patient populations in previous studies (see table 4 in 
the online supplement).    11     –      13        15        16    Treatment showed a very early 
onset of action as the mean DAS28 decreased by 40±20% after 
the ﬁ  rst tocilizumab infusion. At week 24, 57% of the patients 
had achieved the primary end point of LDAS and 47.6% even 
achieved DAS remission. Remarkably, 79.2% of the patients in 
our study had high RA activity with a DAS28 >5.1 at baseline. 
Of important clinical relevance is the fact that tocilizumab treat-
ment was particularly beneﬁ  cial in these patients, 42% of whom 
achieved DAS28 remission by week 24. Furthermore, the qual-
ity of life as reﬂ  ected by the HAQ-DI, SF-36 and fatigue score 
also improved. In all, 75% of the patients reported an overall 
satisfaction with the treatment. 
  Because of the strong effect of tocilizumab on the acute phase 
reactants (APR), it is a matter of debate whether the high remis-
sion rates resulting from tocilizumab are mainly driven by the 
reduction in APR   . This can be rebutted by the strong decrease 
in the number of swollen and tender joints as well as the high 
percentage of patients (26%) with no TJC and no SJC (  ﬁ  gure 1  ). 
were the individual changes clinically signiﬁ   cant at the last 
assessment. Raised aminotransferases were reported in 7.3% of 
patients (5.6% drug-related) and low neutrophil counts in 2.4% 
(all drug-related).     
  DISCUSSION 
  TAMARA was the ﬁ  rst phase IIIb study preceding the approval 
of tocilizumab in January 2009 to be performed in a setting close 
to real-life medical care and conﬁ  rmed the rapid and sustained 
improvement in signs and symptoms of RA with tocilizumab as 
well as a manageable safety proﬁ  le. 
  The TAMARA study was conducted in 286 patients with active 
RA who had received 1–4 previous DMARDs; in 41.6% treatment 
  Table  2         EULAR and ACR responses in RF-positive and RF-negative 
patients at week 24   
 Efﬁ  cacy measure 
 RF-positive 
(n=184) 
 RF-negative 
(n=81) 
Mean±SD DAS28 at baseline 6.1±1.0 5.7±1.1
Remission (DAS28 <2.6) 46.2% (85) 50.6% (41)
LDAS (DAS28 ≤3.2) 57.1% (105) 59.3% (48)
Clinically signiﬁ  cant DAS28 reduction ≥1.2 79.3% (146) 70.4% (57)
EULAR good response 56.0% (103) 58.0% (47)
ACR50 50.5% (93) 50.6% (41)
ACR70 33.7% (62) 34.6% (28)
      Data shown as percentage (n) unless otherwise stated. 
  ACR, American College of Rheumatology; DAS, Disease Activity Score; EULAR, 
European League Against Rheumatism; LDAS, Low Disease Activity Score; RF, 
rheumatoid  factor.   
 Figure  2        (A) Initial course of VAS fatigue, VAS pain and morning stiffness (patient self-reported) from day 1 to day 28 after only one infusion (LOCF) 
(values for day 1 were documented after the ﬁ  rst infusion). (B) Course of fatigue (FACIT-Fatigue) and HAQ-DI in TNF antagonist-IR and DMARD-IR 
patients. In the HAQ-DI, which had the lowest percentage change, the mean absolute change of 0.48 score points can be considered a clinically 
relevant improvement. DMARD-IR, inadequate response to disease-modifying antirheumatic drugs; HAQ-DI, Health Assessment Questionnaire-
Disease Index; LOCF, last observation carried forward; TNF antagonist-IR, inadequate response to TNF antagonists; VAS, visual analogue  scale.       
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  Subgroup analyses revealed a comparable clinical response in 
RF-positive and RF-negative patients that has not been reported 
previously. Patients with concomitant leﬂ  unomide  treatment 
did not differ from the whole cohort with regard to efﬁ  cacy 
parameters and safety, indicating that leﬂ  unomide may repre-
sent a suitable concomitant DMARD. 
  Not unexpectedly, patients who had failed with previous 
DMARDs showed a better clinical response than patients who 
had shown an inadequate response to previous TNF antagonists, 
possibly because of their longer disease duration, the earlier use 
of tocilizumab or because they may have had a less refractory 
form of RA. 
  The treatment with tocilizumab was well tolerated. The inci-
dence rates of all AEs (83.9%) and of drug-related AEs (66.1%) as 
well as the incidence of serious infections were as expected from 
the published reports. Most of the AEs were mild or moderate and 
resolved by the end of the study. The only unexpected serious AE 
in this study was a relapse of a pre-existing but previously undi-
agnosed case of multiple sclerosis (MS) which was rated as drug-
related. This patient had a history of several neurological disorders 
(including unspeciﬁ  ed foci on the MRI), but the diagnosis of MS 
was not established before the study. Reassessment of the medical 
charts, however, conﬁ  rmed the pre-existence of a relapsing-remit-
ting MS and the serious AE was changed to ‘MS-relapse’. Thus, a 
causal relationship with tocilizumab could not be excluded. 
  This study was performed in a setting close to real-life 
medical care; however the non-controlled design and the short 
observation period of 24 weeks provide only limited data 
with respect to long-term efﬁ  cacy and potential safety issues. 
Nevertheless, studies close to real-life medical care in usual 
clinical practice in a heterogeneous patient population have 
a high degree of relevance as results of controlled studies do 
not always match with daily medical care. Only 21–33% of 
patients in the German RABBIT register treated with biological 
agents would have been eligible for the major trials with TNFα 
antagonists. In the clinical setting, the indications for treatment 
with biological agents were not identical to the inclusion cri-
teria for trials, and there was a smaller relative improvement 
achieved in the patients with RA who would not have fulﬁ  lled 
the inclusion criteria of the trials.    18    Interestingly, the hetero-
geneous patient population from the TAMARA study showed 
even better efﬁ  cacy results than patients from previously pub-
lished controlled studies (see table 4 in the online supplement). 
We therefore believe that these data conﬁ  rm that tocilizumab 
represents an important treatment option for patients with RA 
in a real-life setting.   
  CONCLUSIONS 
  This study demonstrated the efﬁ  cacy of tocilizumab in combi-
nation with a traditional DMARD in a heterogeneous patient 
population with moderate to severe active RA. The good efﬁ  -
cacy of tocilizumab was accompanied by a manageable safety 
proﬁ  le, which was in accordance with the safety data obtained 
during the clinical development programme of tocilizumab.     
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